Stimulant and Cannabis Use Disorders

Core Idea

Stimulant and cannabis use disorders involve problematic use despite changing social acceptance. Stimulants produce intense dopamine surges while cannabis affects executive function; both impair reward processing and demonstrate high relapse potential.

Explainer

From your overview of substance use disorders, you know that all addictive drugs share a common currency: they hijack the brain's reward circuitry, ultimately disrupting the dopamine-based learning systems that normally motivate adaptive behavior. Stimulants and cannabis reach this endpoint through very different pharmacological routes, and understanding those routes helps explain why each disorder has a distinct clinical character.

Stimulants — cocaine, amphetamine, methamphetamine — produce their effects by flooding the synapse with dopamine. Cocaine blocks the dopamine reuptake transporter (DAT), preventing clearance; amphetamines additionally reverse the transporter, actively pumping dopamine out of terminals. The result is a massive dopamine surge in the nucleus accumbens — far exceeding what any natural reward produces. The initial high is intense and brief. The crash that follows is equally intense in the opposite direction: as dopamine depletes and receptors downregulate, the user experiences dysphoria, fatigue, and craving. This swing between euphoria and anhedonia is characteristic of stimulant disorders. Over time, the brain's baseline dopamine function degrades — natural rewards (food, connection, achievement) feel flat compared to the drug, and the drug itself produces diminishing pleasure while cravings remain. The disorder becomes one of using not to feel good but to feel anything at all.

Cannabis operates through a different system entirely. The active compound THC binds cannabinoid receptors (CB1), which are widespread in the brain — particularly in the prefrontal cortex, hippocampus, basal ganglia, and cerebellum. These receptors normally respond to endocannabinoids, retrograde messengers that regulate synaptic strength. By flooding these receptors, THC disrupts normal modulation throughout the brain, producing altered sensory experience, time perception, and — critically — impairment of working memory and executive function. Long-term heavy use, especially when started in adolescence during prefrontal development, is associated with lasting deficits in these functions. Cannabis use disorder is distinguished from other substance disorders in that the subjective high is less intense and the withdrawal syndrome (irritability, sleep disruption, appetite changes) is milder. This contributes to the common misconception that cannabis isn't addictive — but the loss of control over use, continued use despite consequences, and impaired functioning meet criteria for disorder regardless of the drug's potency relative to other substances.

Both disorders demonstrate high relapse potential for shared reasons: the drug has trained the reward system to assign enormous motivational value to drug-related cues (pipes, lighters, certain contexts, social situations). These conditioned cues trigger craving months or years into abstinence, because the associative memories formed during use are stored durably. Treatment for both disorders is primarily behavioral — contingency management (rewarding abstinence), cognitive-behavioral strategies for craving management, and motivational interviewing to build intrinsic motivation to change. Neither disorder has FDA-approved pharmacotherapy as of this writing, which contrasts with alcohol and opioid use disorders, and reflects an area of active research.